Safe and informed prescribing of psychotropic medication during the COVID-19 pandemic

Jurjen J Luykx; Sisco M P van Veen; Arne Risselada; Paul Naarding; Joeri K Tijdink; Christiaan H Vinkers

doi:https://doi.org/10.1192/bjp.2020.92

Safe and informed prescribing of psychotropic medication during the COVID-19 pandemic

Jurjen J Luykx, Sisco M P van Veen, Arne Risselada, Paul Naarding, Joeri K Tijdink, Christiaan H Vinkers

Research output: Contribution to journal › Review article › Academic › peer-review

25 Citations (Scopus)

Abstract

Treatment with psychotropic medication may sometimes be jeopardised because of the COVID-19 pandemic. One underlying reason is the lack of COVID-19-specific psychopharmacology guidelines. Here, we discuss five considerations arising from our clinical experience and pharmacological background knowledge to enable safe and well-informed psychopharmacotherapy during the COVID-19 pandemic.

Original language	English
Pages (from-to)	471-474
Number of pages	4
Journal	The British journal of psychiatry : the journal of mental science
Volume	217
Issue number	3
Early online date	4 May 2020
DOIs	https://doi.org/10.1192/bjp.2020.92
Publication status	Published - 1 Sept 2020

Keywords

Anxiety/etiology
Betacoronavirus
COVID-19
Coronavirus Infections/epidemiology
Humans
Inappropriate Prescribing/prevention & control
Medication Therapy Management/standards
Mental Disorders/epidemiology
Mental Health Services/trends
Netherlands/epidemiology
Pandemics
Patient Selection
Pneumonia, Viral/epidemiology
Practice Patterns, Physicians'/standards
Psychotherapy/methods
Psychotropic Drugs/therapeutic use
Telemedicine/methods
epidemiology
prescribing
psychiatry
psychopharmacology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://doi.org/10.1192/bjp.2020.92

Cite this

@article{d2d9e7fdea53443bbe3a7994f59c3544,

title = "Safe and informed prescribing of psychotropic medication during the COVID-19 pandemic",

abstract = "Treatment with psychotropic medication may sometimes be jeopardised because of the COVID-19 pandemic. One underlying reason is the lack of COVID-19-specific psychopharmacology guidelines. Here, we discuss five considerations arising from our clinical experience and pharmacological background knowledge to enable safe and well-informed psychopharmacotherapy during the COVID-19 pandemic.",

keywords = "Anxiety/etiology, Betacoronavirus, COVID-19, Coronavirus Infections/epidemiology, Humans, Inappropriate Prescribing/prevention & control, Medication Therapy Management/standards, Mental Disorders/epidemiology, Mental Health Services/trends, Netherlands/epidemiology, Pandemics, Patient Selection, Pneumonia, Viral/epidemiology, Practice Patterns, Physicians'/standards, Psychotherapy/methods, Psychotropic Drugs/therapeutic use, Telemedicine/methods, epidemiology, prescribing, psychiatry, psychopharmacology",

author = "Luykx, {Jurjen J} and {van Veen}, {Sisco M P} and Arne Risselada and Paul Naarding and Tijdink, {Joeri K} and Vinkers, {Christiaan H}",

year = "2020",

month = sep,

day = "1",

doi = "https://doi.org/10.1192/bjp.2020.92",

language = "English",

volume = "217",

pages = "471--474",

journal = "The British journal of psychiatry : the journal of mental science",

issn = "0007-1250",

publisher = "Royal College of Psychiatrists",

number = "3",

}

TY - JOUR

T1 - Safe and informed prescribing of psychotropic medication during the COVID-19 pandemic

AU - Luykx, Jurjen J

AU - van Veen, Sisco M P

AU - Risselada, Arne

AU - Naarding, Paul

AU - Tijdink, Joeri K

AU - Vinkers, Christiaan H

PY - 2020/9/1

Y1 - 2020/9/1

N2 - Treatment with psychotropic medication may sometimes be jeopardised because of the COVID-19 pandemic. One underlying reason is the lack of COVID-19-specific psychopharmacology guidelines. Here, we discuss five considerations arising from our clinical experience and pharmacological background knowledge to enable safe and well-informed psychopharmacotherapy during the COVID-19 pandemic.

AB - Treatment with psychotropic medication may sometimes be jeopardised because of the COVID-19 pandemic. One underlying reason is the lack of COVID-19-specific psychopharmacology guidelines. Here, we discuss five considerations arising from our clinical experience and pharmacological background knowledge to enable safe and well-informed psychopharmacotherapy during the COVID-19 pandemic.

KW - Anxiety/etiology

KW - Betacoronavirus

KW - COVID-19

KW - Coronavirus Infections/epidemiology

KW - Humans

KW - Inappropriate Prescribing/prevention & control

KW - Medication Therapy Management/standards

KW - Mental Disorders/epidemiology

KW - Mental Health Services/trends

KW - Netherlands/epidemiology

KW - Pandemics

KW - Patient Selection

KW - Pneumonia, Viral/epidemiology

KW - Practice Patterns, Physicians'/standards

KW - Psychotherapy/methods

KW - Psychotropic Drugs/therapeutic use

KW - Telemedicine/methods

KW - epidemiology

KW - prescribing

KW - psychiatry

KW - psychopharmacology

UR - http://www.scopus.com/inward/record.url?scp=85090003086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090003086&partnerID=8YFLogxK

U2 - https://doi.org/10.1192/bjp.2020.92

DO - https://doi.org/10.1192/bjp.2020.92

M3 - Review article

C2 - 32362299

SN - 0007-1250

VL - 217

SP - 471

EP - 474

JO - The British journal of psychiatry : the journal of mental science

JF - The British journal of psychiatry : the journal of mental science

IS - 3

ER -

Safe and informed prescribing of psychotropic medication during the COVID-19 pandemic

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this